Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 06, 2023

Beam Therapeutics Inc.

(State or Other Jurisdiction of Incorporation)

001-39208

(Commission File Number)

81-5238376

(Commission File Number)

(IRS Employer Identification No.)

238 Main Street

Cambridge, Massachusetts

(Address of Principal Executive Offices)

02142

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 327-8775

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, par value $0.01 per share</td>
<td>BEAM</td>
<td>Nasdaq Global Select Market</td>
</tr>
</tbody>
</table>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 6, 2023, Beam Therapeutics Inc. (the “Company”) held its 2023 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 21, 2023 (the “Proxy Statement”).

Proposal 1 – Each of the following nominees were elected as Class III directors to serve on the Company’s board of directors until the Company’s 2026 annual meeting of stockholders, and until their respective successors have been duly elected and qualified, based on the following votes:

<table>
<thead>
<tr>
<th>Nominee</th>
<th>For</th>
<th>Against</th>
<th>Abstentions</th>
<th>Broker Non-Votes</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Evans</td>
<td>48,704,446</td>
<td>250,291</td>
<td>124,211</td>
<td>11,303,038</td>
</tr>
<tr>
<td>John Maraganore, Ph.D.</td>
<td>41,623,856</td>
<td>7,441,072</td>
<td>14,020</td>
<td>11,303,038</td>
</tr>
</tbody>
</table>

Proposal 2 – The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was ratified, based on the following votes:

<table>
<thead>
<tr>
<th></th>
<th>For</th>
<th>Against</th>
<th>Abstentions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60,120,184</td>
<td>31,889</td>
<td>229,913</td>
</tr>
</tbody>
</table>

Proposal 3 – The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following votes:

<table>
<thead>
<tr>
<th></th>
<th>For</th>
<th>Against</th>
<th>Abstentions</th>
<th>Broker Non-Votes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>47,040,443</td>
<td>1,996,717</td>
<td>41,788</td>
<td>11,303,038</td>
</tr>
</tbody>
</table>
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BEAM THERAPEUTICS INC.

Date: June 8, 2023

By: /s/ John Evans
Chief Executive Officer